Chloroquine has tumor‑inhibitory and tumor‑promoting effects in triple‑negative breast cancer

Tuomela,Johanna; Sandholm,Jouko; Kauppila,Joonas  H.; Lehenkari,Petri; Harris,Kevin  W.; Selander,Katri  S.

doi:10.3892/ol.2013.1602

Chloroquine has tumor‑inhibitory and tumor‑promoting effects in triple‑negative breast cancer

Authors:
- Johanna Tuomela
- Jouko Sandholm
- Joonas H. Kauppila
- Petri Lehenkari
- Kevin W. Harris
- Katri S. Selander
View Affiliations

Affiliations: Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA, Department of Anatomy and Cell Biology, University of Oulu, Oulu 90014, Finland
Published online on: October 4, 2013 https://doi.org/10.3892/ol.2013.1602
Pages: 1665-1672

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Toll‑like receptor‑9 (TLR9) is an intracellular DNA receptor that is widely expressed in breast and other cancers. We previously demonstrated that low tumor TLR9 expression upon diagnosis is associated with significantly shortened disease‑specific survival times in patients with triple‑negative breast cancer (TNBC). There are no targeted therapies for this subgroup of patients whose prognosis is among the worst in breast cancer. Due to the previously detected in vitro anti‑invasive effects of chloroquine in these cell lines, the present study aimed to investigate the in vivo effects of chloroquine against two clinical subtypes of TNBC that differ in TLR9 expression. Chloroquine suppressed matrix metalloproteinase (MMP)‑2 and MMP‑9 mRNA expression and protein activity, whereas MMP‑13 mRNA expression and proteolytic activity were increased. Despite enhancing TLR9 mRNA expression, chloroquine suppressed TLR9 protein expression in vitro. Daily treatment of mice with intraperitoneal (i.p.) chloroquine (80 mg/kg/day) for 22 days, did not inhibit the growth of control siRNA or TLR9 siRNA MDA‑MB‑231 breast cancer cells. In conclusion, despite the favorable in vitro effects on TNBC invasion and viability, particularly in hypoxic conditions, chloroquine does not prevent the growth of the triple‑negative MDA‑MB‑231 cells with high or low TLR9 expression levels in vivo. This may be explained by the activating effects of chloroquine on MMP‑13 expression or by the fact that chloroquine, by suppressing TLR9 expression, permits the activation of currently unknown molecular pathways, which allow the aggressive behavior of TNBC cells with low TLR9 expression in hypoxia.

View Figures

View References

1	Elias AD: Triple-negative breast cancer: a short review. Am J Clin Oncol. 33:637–645. 2010. View Article : Google Scholar : PubMed/NCBI
2	Carotenuto P, Roma C, Rachiglio AM, Botti G, D’Alessio A and Normanno N: Triple negative breast cancer: from molecular portrait to therapeutic intervention. Crit Rev Eukaryot Gene Expr. 20:17–34. 2010. View Article : Google Scholar : PubMed/NCBI
3	Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K and Akira S: A Toll-like receptor recognizes bacterial DNA. Nature. 408:740–745. 2000. View Article : Google Scholar : PubMed/NCBI
4	Di JM, Pang J, Pu XY, Zhang Y, Liu XP, Fang YQ, Ruan XX and Gao X: Toll-like receptor 9 agonists promote IL-8 and TGF-beta1 production via activation of nuclear factor kappaB in PC-3 cells. Cancer Genet Cytogenet. 192:60–67. 2009. View Article : Google Scholar : PubMed/NCBI
5	Assaf A, Esteves H, Curnow SJ and Browning MJ: A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines. Cell Immunol. 259:90–99. 2009. View Article : Google Scholar : PubMed/NCBI
6	Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, Jukkola-Vuorinen A, Vuopala KS, Harris KW, et al: Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res. 6:1534–1543. 2008. View Article : Google Scholar : PubMed/NCBI
7	Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW and Selander KS: Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate. 67:774–781. 2007. View Article : Google Scholar : PubMed/NCBI
8	Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW and Selander KS: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 4:437–447. 2006. View Article : Google Scholar : PubMed/NCBI
9	Tuomela J, Sandholm J, Karihtala P, Ilvesaro J, Vuopala KS, Kauppila JH, Kauppila S, Chen D, Pressey C, Härkönen P, et al: Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer. Breast Cancer Res Treat. 135:481–493. 2012. View Article : Google Scholar : PubMed/NCBI
10	Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, et al: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515–527. 2006. View Article : Google Scholar : PubMed/NCBI
11	Sandholm J, Kauppila JH, Pressey C, Tuomela J, Jukkola-Vuorinen A, Vaarala M, Johnson MR, Harris KW and Selander KS: Estrogen receptor-α and sex steroid hormones regulate Toll-like receptor-9 expression and invasive function in human breast cancer cells. Breast Cancer Res Treat. 132:411–419. 2012.
12	Chaudary N and Hill RP: Hypoxia and metastasis in breast cancer. Breast Dis. 26:55–64. 2007.
13	Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL and Quigley JP: Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem. 274:13066–13076. 1999. View Article : Google Scholar : PubMed/NCBI
14	Yeomans ND: Aspirin: old drug, new uses and challenges. J Gastroenterol Hepatol. 26:426–431. 2011. View Article : Google Scholar : PubMed/NCBI
15	Vazquez-Martin A, López-Bonetc E, Cufi S, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B and Menendez JA: Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat. 14:212–223. 2011. View Article : Google Scholar : PubMed/NCBI
16	Solomon VR, Hu C and Lee H: Design and synthesis of chloroquine analogs with anti-breast cancer property. Eur J Med Chem. 45:3916–3923. 2010. View Article : Google Scholar : PubMed/NCBI
17	Espina V, Mariani BD, Gallagher RI, Tran K, Banks S, Wiedemann J, Huryk H, Mueller C, Adamo L, Deng J, et al: Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One. 5:e102402010. View Article : Google Scholar : PubMed/NCBI
18	Hu C, Raja Solomon V, Cano P and Lee H: A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells. Eur J Med Chem. 45:705–709. 2010. View Article : Google Scholar : PubMed/NCBI
19	Rahim R and Strobl JS: Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs. 20:736–745. 2009. View Article : Google Scholar : PubMed/NCBI
20	Loehberg CR, Thompson T, Kastan MB, Maclean KH, Edwards DG, Kittrell FS, Medina D, Conneely OM and O’Malley BW: Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. Cancer Res. 67:12026–12033. 2007. View Article : Google Scholar : PubMed/NCBI
21	Loehberg CR, Strissel PL, Dittrich R, Strick R, Dittmer J, Dittmer A, Fabry B, Kalender WA, Koch T, Wachter DL, et al: Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the mTOR inhibitor RAD001. Biochem Pharmacol. 83:480–488. 2012. View Article : Google Scholar : PubMed/NCBI
22	Jiang PD, Zhao YL, Deng XQ, Mao YQ, Shi W, Tang QQ, Li ZG, Zheng YZ, Yang SY and Wei YQ: Antitumor and antimetastatic activities of chloroquine diphosphate in a murine model of breast cancer. Biomed Pharmacother. 64:609–614. 2010. View Article : Google Scholar : PubMed/NCBI
23	Yerlikaya A, Okur E and Ulukaya E: The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib. Tumour Biol. 33:1385–1392. 2012. View Article : Google Scholar : PubMed/NCBI
24	Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B and Jerala R: Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 186:4794–4804. 2011. View Article : Google Scholar : PubMed/NCBI
25	Zhu X, Pan Y, Li Y, Jiang Y, Shang H, Gowda DC, Cui L and Cao Y: Targeting Toll-like receptors by chloroquine protects mice from experimental cerebral malaria. Int Immunopharmacol. 13:392–397. 2012. View Article : Google Scholar : PubMed/NCBI